PRIMARY STUDY
Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats
Key Findings: Δ9-THCV reduced seizure activity in both in vitro rat piriform cortex models and in vivo rat seizure models.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): United Kingdom
Year of Pub: 2021
Cannabinoids Studied: Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Unspecified
Receptors Studied: CB1
Ligands Studied: GABA
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: In vitro, Injection
Cannabinoid Ratio: (THCV) 0 
Dosing Regimen: Δ9-THCV (0.025-2.5 mg/kg)
Clinical Relevance: Δ9-THCV exerts antiepileptiform and anticonvulsant properties and has possible therapeutic application in the treatment of pathophysiologic hyperexcitability states in humans. The mechanism of action is consistent with CB1 receptor activity.
Additional Notes: Pharmacodynamic Study Data
Link to study
